Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers
Bioorganic & Medicinal Chemistry Letters · 2025
DOI: 10.1016/j.bmcl.2025.130141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Byul Moon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, South Korea. Hauptthemen laut MEDLINE: Werner Syndrome Helicase, Colorectal Neoplasms, Cell Proliferation, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Research Institute of Chemical Technology, National Research Foundation of Korea, Korea Research Institute of Bioscience & Biotechnology.
Abstract (Originalsprache)
The Werner protein, WRN, is a member of the RecQ helicase family implicated in genome maintenance. Several large-scale functional genomics screens have identified WRN as a synthetic lethal target in cancer cell lines with microsatellite instability-high (MSI-H). Accordingly, WRN is considered a potential therapeutic target in MSI-H cancers. HRO761, a non-covalent WRN inhibitor developed by Novartis, entered clinical trial for patients with MSI-H colorectal cancer (CRC). In this study, we investigated bioisosteric replacement of the hydroxyl pyrimidine residue of HRO761 with several bicyclic structures to obtain a novel chemical entity. In vitro ATPase and cell proliferation assays revealed two candidate chemicals that showed similar or better effects than HRO761. Additionally, an in vivo study demonstrated that KWR095, a newly synthesized WRN inhibitor, has significant anti-proliferative effects compared with vehicle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, South Korea.
- Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
- DiseaseTarget Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea.
- Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea; Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon 34113…
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 34141, South Korea.
- DiseaseTarget Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea; KRIBB School of Bioscience, Korea University of Science and Technology (UST), Daejeon 34113,…
Förderung
- Korea Research Institute of Chemical Technology
- National Research Foundation of Korea
- Korea Research Institute of Bioscience & Biotechnology
- Korea Ministry of Science and ICT
Zitieren
APA
Moon, B., Go, A., Park, S., Kim, H. J., An, D., Kim, J., Lee, J. Y., Kim, J. H., Hwang, J. Y., & Kim, J. A. (2025). Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130141
Vancouver
Moon B, Go A, Park S, Kim HJ, An D, Kim J, et al. Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130141
BibTeX
@article{Moon2025,
author = {Moon, Byul and Go, Ahra and Park, Seulki and Kim, Hyun Jin and An, Dongju and Kim, Jaehoon and Lee, Joo-Youn and Kim, Jeong-Hoon and Hwang, Jong Yeon and Kim, Jung-Ae},
title = {Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2025},
doi = {10.1016/j.bmcl.2025.130141}
}
EUVIMED